Appreciate it, and yes that's essentially the point. The concern isn't finerenone specifically. It's that finerenone is almost exclusively metabolised by CYP3A4, and the PED community routinely runs compounds that either inhibit or compete at that exact enzyme — berberine, PDE5 inhibitors, certain AIs, suspectfully grapefruit. Stack those on top of finerenone and you're not just adding a cardioprotective drug, you're potentially elevating finerenone levels in ways that weren't studied in any clinical trial. Toss in the interindividual SNP variants on top of that and you have no idea where you're landing pharmacokinetically. That's the FAFO arena I'm suggesting to the masses to be vigilant awareness about.
And while we're on FAFO — if hyperkalemia does develop acutely in this stack, do you have calcium gluconate or calcium chloride on hand to stabilise the cardiac membrane? Insulin and dextrose to drive potassium intracellularly? A beta-2 agonist as a temporising measure? Because that's the acute management an ER would use for severe hyperkalemia. Most people running this combination at home have none of the above.
Appreciate the nudge the OP mistakenly stated prolactin. I would agree, he most likely meant progesterone.
The tone wasn't negative, it was precise. There's a difference. I didn’t shut the topic down. The pushback was specifically on extrapolating diseased-population trial data to a PED context without acknowledging the pharmacokinetic variables that make that extrapolation genuinely problematic. If anything that's what makes the discussion worth having.
And no— the point wasn't "bathtub tren bad." The point was if you're running finerenone alongside an ARB, nebivolol, Jardiance (SGLT-2I), then toss in a PDE5I and whatever else is in the stack, and you have zero idea what your CYP3A4 genotype looks like, you should probably understand the drug interaction landscape before calling it prophylactic cardioprotection. That's not negativity. That's the bare minimum due diligence the topic deserves.
As for the German guys. This fits right in-line of my commentaries to
@SouthernMuscle of painting a different picture when we include allelic heterogeneity. If they're of European descent, they're in a population where CYP3A4*22 runs at 5-7% frequency. That's a reduced function variant that demonstrably lowers CYP3A4 enzymatic activity and raises exposure to substrates like finerenone. And it's carried silently with zero clinical awareness unless someone's actually been genotyped. Your German contacts are a textbook example of exactly the interindividual SNP unknown the discussion raised.
Is the OP have intentions of checking his K+ shortly after running this polypharmacy? Then periodically monitor it? That would be a wise idea IMO.
Are these topics not supposed to run deep in awareness?
